Jubilant Organosys, an integrated pharmaceutical industry player and the largest CRAMS company in India, has posted a 210 per cent rise in its net profits during the first quarter ended June 2007. The company's net profit during this period rose to Rs 142.9 crore against Rs 46.1 crore during the corresponding period last year.

Simultaneously, the company's net sales also increased by 31 per cent to Rs 540.0 crore against Rs 411.2 crore during the same period last year. The company reported other income, which includes Rs 879 million as exchange gain on foreign currency loans including FCCB.

Commenting on the company's performance, Shyam S Bhartia, chairman and managing director and Hari S Bhartia, co-chairman and managing director, Jubilant Organosys Ltd, said, "Jubilant's strategy of going to market as a full-suite, integrated, outsourcing partner is paying richly at a time when global pharma is increasingly looking eastward to meet production and research needs".

Revenues from the Phrama and Life Science Products and Service (PLSPS) business grew by 51.1per cent at Rs 311.3 crore compared to Rs 206.0 crore last year. The revenues from the PLSPS segment include one-month sales of Hollister-Stier Laboratories (Hollister) whose acquisition was completed by the company on June 01, 2007. Revenue growth in industrial and performance products at 11.5 per cent remained healthy. International sales at Rs 278.9 crore grew by 57.9 per cent as compared to Rs 176.6 crore last year. Total international sales also stood at 51.6 per cent of the net sales of the company.

The corresponding diluted EPS was at Rs 8.02 on Rs 1 paid up equity share. On the standalone basis, the company's net profits changed from Rs 47.4crore to Rs.138.4 crore thus giving an EPS diluted of Rs 7.77 for the current quarter.